Jounce Therapeutics is dedicated to transforming the treatment of cancer
Jounce is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce's proprietary product engine has the potential to discover novel biological insights to drive the development of new immunotherapy treatments with durable responses, extending and improving patients' quality of life.
02/14/2013
Third Rock Ventures Launches Jounce Therapeutics with $47 Million Series A to Transform Cancer Treatment
Read More > >